Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial

OBJECTIVES: To assess the effects of rivastigmine on the core domains of Alzheimer’s disease. DESIGN: Prospective, randomised, multicentre, double blind, placebo controlled, parallel group trial. Patients received either placebo, 1-4 mg/day (lower dose) rivastigmine, or 6-12 mg/day (higher dose) riv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rösler, Michael, Anand, Ravi, Cicin-Sain, Ana, Gauthier, Serge, Agid, Yves, Dal-Bianco, Peter, Stähelin, Hannes B, Hartman, Richard, Gharabawi, Marguirguis
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 1999
Assuntos:
Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC27767/
https://ncbi.nlm.nih.gov/pubmed/10066203
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados